NEW YORK – Adaptive Biotechnologies announced Wednesday after the close of the market the pricing of a public offering of common stock that is expected to bring in gross proceeds of around $240 million for the firm.
The offering consists of 8 million shares of common stock, including 6 million being sold by Adaptive and 2 million being sold by a shareholder, at a price of $40 per share. Adaptive has granted the underwriters a 30-day option to purchase up to 1.2 million additional shares at the offering price, less underwriting discounts and commissions.